Greywolf Therapeutics
Abingdon
About Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $122.3M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2024)
- Website: greywolftherapeutics.com
- Phone: +44 1865 292 038
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/greywolf-therapeutics-105840 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.